Explore

Rapid Read Rapid Read
Webinar Highlights Concerns Over SSRIs for Pregnant Women and Teens

Webinar Highlights Concerns Over SSRIs for Pregnant Women and Teens

A recent webinar titled 'Docket & Dose' featured a discussion on the use of Selective Serotonin Reuptake Inhibitors (SSRIs) among pregnant women and teenagers. The event, held on May 7, 2026, included insights from Kim Witczak, a drug safety advocate, alongside Wayne Rohde and Dr. James Lyons-Weiler. The conversation focused on the risks associated with SSRIs, including issues of informed consent, withdrawal symptoms, and the potential for adverse effects such as suicidality and emotional blunting. The discussion also addressed the role of pharmaceutical marketing and the oversight of the Food and Drug Administration (FDA) in communicating these risks. Witczak, who became an advocate following her husband's death after being prescribed Zoloft, emphasized the need for transparency and accountability in drug safety, particularly for vulnerable groups like pregnant women and adolescents.
Rapid Read Rapid Read
FDA Approves Fruit-Flavored E-Cigarettes for Adults Following Industry Appeals

FDA Approves Fruit-Flavored E-Cigarettes for Adults Following Industry Appeals

The U.S. Food and Drug Administration (FDA) has granted its first authorization for fruit-flavored electronic cigarettes specifically intended for adult smokers. This decision marks a significant policy shift, coming after months of lobbying from the vaping industry to President Trump. The authorization allows these products to be marketed to adults, potentially expanding the options available to smokers seeking alternatives to traditional tobacco products. The move is seen as a response to the vaping industry's efforts to provide adult smokers with more appealing options, while still maintaining regulatory oversight to prevent underage usage.
Trendline Trendline
Harbour BioMed Receives FDA Clearance for HBM7004 to Treat Advanced Solid Tumors

Harbour BioMed Receives FDA Clearance for HBM7004 to Treat Advanced Solid Tumors

Harbour BioMed Receives FDA Clearance for HBM7004 to Treat Advanced Solid Tumors
Reuters Reuters
Exclusive-Kennedy's health officials explored US ban of some widely used antidepressants, sources say

Exclusive-Kennedy's health officials explored US ban of some widely used antidepressants, sources say

By Yasmeen Abutaleb and Bo Erickson WASHINGTON, May 8 (Reuters) - U.S. health department officials last week explored whether they could ban certain drugs in a widely prescribed class of antidepressants as Health Secretary Robert F.
Trendline Trendline
Whoop Introduces On-Demand Clinician Access for U.S. Users with New Health Features

Whoop Introduces On-Demand Clinician Access for U.S. Users with New Health Features

Whoop Introduces On-Demand Clinician Access for U.S. Users with New Health Features
Rapid Read Rapid Read
FDA and Paradigm Health Collaborate to Accelerate Clinical Trials

FDA and Paradigm Health Collaborate to Accelerate Clinical Trials

The FDA has announced a collaboration with Paradigm Health to expedite clinical trial processes using an AI-powered platform. This initiative aims to streamline data collection and regulatory review by integrating electronic health records (EHRs) and transmitting critical safety and efficacy signals to pharmaceutical sponsors and the FDA. The collaboration is designed to reduce manual data entry and unnecessary data transfers, thereby accelerating the drug development process. The platform is already operational with early partners like Amgen and AstraZeneca, with trials underway at major research institutions.
Trendline Trendline
Pierre Fabre Pharmaceuticals Aligns with FDA for Tabelecleucel BLA Resubmission

Pierre Fabre Pharmaceuticals Aligns with FDA for Tabelecleucel BLA Resubmission

Pierre Fabre Pharmaceuticals Aligns with FDA for Tabelecleucel BLA Resubmission
AP News AP News
FDA's new playbook: Lots of media announcements but not much rulemaking

FDA's new playbook: Lots of media announcements but not much rulemaking

Health Secretary Robert F. Kennedy Jr. and other health officials have repeatedly announced major changes before any new rules have been drafted
Trendline Trendline
Michael Clinton Discusses Longevity Habits from His Book 'Longevity Nation'

Michael Clinton Discusses Longevity Habits from His Book 'Longevity Nation'

Michael Clinton Discusses Longevity Habits from His Book 'Longevity Nation'
AP News AP News
FDA announces its first OK of fruit-flavored e-cigarettes for adults in major shift under Trump

FDA announces its first OK of fruit-flavored e-cigarettes for adults in major shift under Trump

U.S. health regulators have announced their first authorization of fruit-flavored electronic cigarettes intended for adult smokers
Rapid Read Rapid Read
American Medical Association Urges Congress to Regulate AI Mental Health Chatbots for Patient Safety

American Medical Association Urges Congress to Regulate AI Mental Health Chatbots for Patient Safety

The American Medical Association (AMA) is calling on Congress to implement stronger regulations for artificial intelligence (AI) in healthcare, particularly concerning mental health chatbots. The AMA has expressed concerns that the rapid adoption of these AI tools is outpacing the necessary safeguards to protect patients. In communications with congressional caucuses focused on AI and digital health, the AMA highlighted the potential of AI to enhance access to mental health support and innovate care delivery. However, it also pointed out significant risks, including misinformation, emotional dependency, privacy breaches, and inappropriate responses from chatbots to users in distress. AMA CEO John Whyte emphasized the need for consistent safeguards to prevent harm and maintain patient trust. The AMA's recommendations include ensuring transparency so users know when they are interacting with AI, setting boundaries to prevent chatbots from posing as licensed professionals, and establishing regulatory definiti...
Trendline Trendline
Diakonos Oncology's DOC1021 Receives FDA Fast Track for Melanoma Treatment

Diakonos Oncology's DOC1021 Receives FDA Fast Track for Melanoma Treatment

Diakonos Oncology's DOC1021 Receives FDA Fast Track for Melanoma Treatment